Welcome!

News Feed Item

PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022

NEW YORK, Jan. 16, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01957666/PharmaPoint-Hemophilia-A-and-B---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022

Summary

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Treatment options in China are extremely limited compared with the 7MM. Although some recombinant replacement therapies for hemophilia A and B, such as Recombinate, Xyntha, Kogenate, Advate and BeneFIX, are approved for marketing in China, they are not covered by national or provisional insurance programs and access to these drugs is extremely limited.

Scope

- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting China Hemophilia A and B market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in China
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis and Quality of Life 16

3.2 Symptoms 17
3.2.1 Hemophilia A and B 17
3.2.2 Inhibitors 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Hemophilia A and B Diagnosis 20
4.1.2 Hemophilia A and B Treatment 20
4.1.3 Inhibitors Diagnosis 22
4.1.4 Inhibitors Treatment 22
4.2 China 24
4.2.1 Clinical Practice 24
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitive Assessment 27
5.3 Product Profiles - Major Brands, Hemophilia A 31
5.3.1 Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 31
5.3.2 Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 35
5.3.3 Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 38
5.4 Product Profiles - Hemophilia B 40
5.4.1 BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 40
5.4.2 Rixubis (BAX-326) 43
5.5 Product Profiles - Hemophilia A and B with Inhibitors 46
5.5.1 NovoSeven RT (coagulation factor VIIa [recombinant]) 46

6 Opportunity and Unmet Need 48
6.1 Overview 48
6.2 Opportunities Analysis 49
6.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections 49
6.2.2 Lower-Cost Recombinant Replacement Therapies 50
6.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients 51
6.2.4 More Convenient Drug Administration 51
6.2.5 Oral Formulation of Recombinant Replacement Therapies 52
6.3 Unmet Needs Gap Analysis 52
6.3.1 Long-Acting FVIII Replacement Therapies 52
6.3.2 Gene Therapy Treatments for Hemophilia A and B 53
7 Pipeline Assessment 54
7.1 Overview 54
7.2 Promising Drugs in Clinical Development - Hemophilia A 54
7.2.1 BAY 94-9027 (octocog alfa) 56
7.2.2 BAX-855 59
7.2.3 Novoeight (turoctocog alfa; NN7008) 63
7.2.4 N8-GP (NN7088) 66
8 Market Outlook 70
8.1 China 70
8.1.1 Forecast 70
8.1.2 Key Events 73
8.1.3 Drivers and Barriers 73
9 Appendix 75
9.1 Bibliography 75
9.2 Abbreviations 83

9.3 Methodology 86
9.4 Forecasting Methodology 86
9.4.1 Diagnosed Hemophilia Patients 87
9.4.2 Percent Drug-Treated Patients 87
9.4.3 Drugs Included in Each Therapeutic Class 88
9.4.4 Launch and Patent Expiry Dates 88
9.4.5 General Pricing Assumptions 89
9.4.6 Individual Drug Assumptions 89
9.4.7 Pricing of Pipeline Agents 92
9.5 Physicians and Specialists Included in this Study 93
9.6 About the Authors 95
9.6.1 Authors 95
9.6.2 Global Head of Healthcare 96
9.7 About GlobalData 97
9.8 Disclaimer 97

1.1 List of Tables

Table 1: Symptoms of Hemophilia A and B 18
Table 2: Most Prescribed Hemophilia A and B Drugs in the Global Markets, 2013 23
Table 3: Leading Recombinant Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2013 29
Table 4: Leading Plasma-Based Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2012 30
Table 5: Product Profile - Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 32
Table 6: Advate SWOT Analysis, 2013 34
Table 7: Product Profile - Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 36
Table 8: Kogenate FS/Helixate FS SWOT Analysis, 2013 38
Table 9: Product Profile - Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 39

Table 10: Recombinate SWOT Analysis, 2013 40
Table 11: Product Profile - BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 41
Table 12: BeneFIX SWOT Analysis, 2013 42
Table 13: Product Profile - Rixubis (BAX-326) 44
Table 14: Rixubis SWOT Analysis, 2013 45
Table 15: Product Profile - NovoSeven RT (coagulation factor VIIa [recombinant]) 46
Table 16: NovoSeven RT SWOT Analysis, 2013 47
Table 17: Overall Unmet Needs - Current Level of Attainment 49
Table 18: Hemophilia A - Phase I/II Pipeline, 2013 54
Table 19: Hemophilia A - Phase III Pipeline, 2013 55
Table 20: Product Profile - BAY 94-9027 56
Table 21: BAY 94-9027 SWOT Analysis, 2013 59
Table 22: Product Profile - BAX-855 60
Table 23: BAX-855 SWOT Analysis, 2013 62
Table 24: Product Profile - Novoeight (turoctocog alfa; NN7008) 63
Table 25: Novoeight SWOT Analysis, 2013 66
Table 26: Product Profile - N8-GP (NN7088) 67
Table 27: N8-GP SWOT Analysis, 2013 69
Table 28: Sales Forecasts ($m) for Hemophilia A and B in China, 2012-2022 71
Table 29: Key Events Impacting Sales for Hemophilia A and B in China, 2013 73
Table 30: Chinese Hemophilia A and B Market - Drivers and Barriers, 2013 73
Table 31: Product Launch Dates 88
Table 32: Physicians Surveyed 93

1.2 List of Figures

Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia A, 2012-2022 55
Figure 2: Sales for Hemophilia A and B in China by Drug Class, 2012-2022 72

To order this report: PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01957666/PharmaPoint-Hemophilia-A-and-B---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...
"I focus on what we are calling CAST Highlight, which is our SaaS application portfolio analysis tool. It is an extremely lightweight tool that can integrate with pretty much any build process right now," explained Andrew Siegmund, Application Migration Specialist for CAST, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that's no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, explored how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He expla...
SYS-CON Events announced today that Evatronix will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Evatronix SA offers comprehensive solutions in the design and implementation of electronic systems, in CAD / CAM deployment, and also is a designer and manufacturer of advanced 3D scanners for professional applications.
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone inn...
Cloud Expo | DXWorld Expo have announced the conference tracks for Cloud Expo 2018. Cloud Expo will be held June 5-7, 2018, at the Javits Center in New York City, and November 6-8, 2018, at the Santa Clara Convention Center, Santa Clara, CA. Digital Transformation (DX) is a major focus with the introduction of DX Expo within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive ov...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
Continuous Delivery makes it possible to exploit findings of cognitive psychology and neuroscience to increase the productivity and happiness of our teams. In his session at 22nd Cloud Expo | DXWorld Expo, Daniel Jones, CTO of EngineerBetter, will answer: How can we improve willpower and decrease technical debt? Is the present bias real? How can we turn it to our advantage? Can you increase a team’s effective IQ? How do DevOps & Product Teams increase empathy, and what impact does empath...
DevOps promotes continuous improvement through a culture of collaboration. But in real terms, how do you: Integrate activities across diverse teams and services? Make objective decisions with system-wide visibility? Use feedback loops to enable learning and improvement? With technology insights and real-world examples, in his general session at @DevOpsSummit, at 21st Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, explored how leading organizations use data-driven DevOps to close th...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, discussed how given the magnitude of today's application ...
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...